All Stories

  1. Kinases and Cancer

    Article • Cancers, March 2018, MDPI AG

    Jonas Cicenas

  2. JNK, p38, ERK, and SGK1 Inhibitors in Cancer

    Article • Cancers, December 2017, MDPI AG

    Jonas Cicenas

  3. Molecular modeling and structure-based drug discovery approach reveals protein kinases as off-targets for novel anticancer drug RH1

    Article • Medical Oncology, September 2017, Springer Science + Business Media

    Jonas Cicenas

  4. KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 Mutations in Pancreatic Cancer

    Article • Cancers, April 2017, MDPI AG

    Jonas Cicenas

  5. The expression of cancer stem cell markers in human colorectal carcinoma cells in a microenvironment dependent manner

    Article • Biochemical and Biophysical Research Communications, March 2017, Elsevier

    Jonas Cicenas

  6. KRAS, NRAS and BRAF mutations in colorectal cancer and melanoma

    Article • Medical Oncology, January 2017, Springer Science + Business Media

    Jonas Cicenas

  7. Metabolomics in pancreatic cancer biomarkers research

    Article • Medical Oncology, November 2016, Springer Science + Business Media

    Jonas Cicenas

  8. Current Role of Proteomics in Pancreatic Cancer Biomarkers Research

    Article • Current Proteomics, April 2016, Bentham Science Publishers

    Jonas Cicenas

  9. Multi-kinase inhibitors, AURKs and cancer

    Article • Medical Oncology, April 2016, Springer Science + Business Media

    Jonas Cicenas

  10. Quantitative proteomic analysis of anticancer drug RH1 resistance in liver carcinoma

    Article • Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics, February 2016, Elsevier

    Jonas Cicenas

  11. JNK inhibitors: is there a future?

    Article • MAP Kinase, December 2015, PAGEPress Publications

    Jonas Cicenas

  12. Highlights of the Latest Advances in Research on CDK Inhibitors

    Article • Cancers, October 2014, MDPI AG

    Jonas Cicenas, Dr. Deividas Valiunas

  13. The CDK inhibitors in cancer research and therapy

    Article • Journal of Cancer Research and Clinical Oncology, August 2011, Springer Science + Business Media

    Jonas Cicenas

  14. Increased Level of Phosphorylated ShcA Measured by Chemiluminescence-Linked Immunoassay Is a Predictor of Good Prognosis in Primary Breast Cancer Expressing Low Levels of Estrogen Receptor

    Article • Cancers, March 2010, MDPI AG

    Jonas Cicenas

  15. Phosphorylation of tyrosine 1248-ERBB2 measured by chemiluminescence-linked immunoassay is an independent predictor of poor prognosis in primary breast cancer patients

    Article • European Journal of Cancer, March 2006, Elsevier

    Jonas Cicenas

  16. Protein chip based miniaturized assay for the simultaneous quantitative monitoring of cancer biomarkers in tissue extracts

    Article • PROTEOMICS, March 2006, Wiley

    Jonas Cicenas

  17. Increased level of phosphorylated akt measured by chemiluminescence-linked immunosorbent assay is a predictor of poor prognosis in primary breast cancer overexpressing ErbB-2

    Article • March 2005, Springer Science + Business Media

    Jonas Cicenas